Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia

Resistance to imatinib (Gleevec®) in cancer cells is frequently because of acquired point mutations in the kinase domain of BCR-ABL. Ponatinib, also known as AP24534, is an oral multi-targeted tyrosine kinase inhibitor (TKI), and it has been investigated in a pivotal phase 2 clinical trial. The hist...

Descripción completa

Detalles Bibliográficos
Autores principales: Okabe, Seiichi, Tauchi, Tetsuzo, Kimura, Shinya, Maekawa, Taira, Kitahara, Toshihiko, Tanaka, Yoko, Ohyashiki, Kazuma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938434/
https://www.ncbi.nlm.nih.gov/pubmed/24586514
http://dx.doi.org/10.1371/journal.pone.0089080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938434/
https://www.ncbi.nlm.nih.gov/pubmed/24586514
http://dx.doi.org/10.1371/journal.pone.0089080

Ejemplares similares